Clinical trial · no report yet · Phase 1
NCT06215118
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
- NCT06215118 ↗
- Active not recruiting
- Pfizer
- 18 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 11 | |
| X threads | 5 | |
| Podcasts | 1 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA
- Phase
- Phase 1
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Elranatamab; Iberdomide
- Arms
- Part 1 Dose Escalation · Experimental
- Part 2 Dose Randomization · Experimental
- Enrollment
- 100
- Primary outcomes
- Part 1: Number of participants with dose limiting toxicity (DLT)
- Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment
- Sponsor
- Pfizer with Bristol-Myers Squibb
- Start
- Feb 20, 2024
- Primary completion
- Nov 16, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06215118 · updated Sep 15, 2026